Cyclotheonellazoles A–C, Potent Protease Inhibitors from the Marine Sponge *Theonella* aff. *swinhoei*

Michal Issac,[†] Maurice Akinin,[‡] Anne Gauvin-Bialecki,[‡] Nicole De Voogd,[§] Alisson Ledoux,[⊥] Michel Frederich,[⊥] Yoel Kashman,[†] and Shmuel Carmeli^{*,†,⊥}

[†]School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel

[‡]Laboratoire de Chimie des Substances Naturelles et des Aliments, Faculté des Sciences et Technologies, Université de La Réunion, 15 Avenue René Cassin, CS 92 003, 97 744, Saint-Denis, Cedex 9, France

[§]Naturalis Biodiversity Center, P.O. Box 9517, 2300 RA, Leiden, The Netherlands

[⊥]Laboratory of Pharmacognosy, Department of Pharmacy, CIRM, University of Liège, B36, 4000 Liège, Belgium

Supporting Information

ABSTRACT: The extract of a sample of the sponge *Theonella* aff. *swinhoei* collected in Madagascar exhibited promising in vitro antiplasmodial activity. The antiplasmodial activity was ascribed in part to the known metabolite swinholide A. Further investigation of the extract afforded three unusual cyclic peptides, cyclotheonellazoles A–C (1–3), which contain six nonproteinogenic amino acids out of the eight acid units that compose these natural products. Among these acids the most novel were 4-propenoyl-2-tyrosylthiazole and 3-amino-4-methyl-2-oxohexanoic acid. The structure of the compounds was elucidated by interpretation of the 1D and 2D NMR data, HRESIMS, and advanced Merfay's techniques. The new compounds were found to be nanomolar inhibitors of chymotrypsin and sub-nanomolar inhibitors of elastase, but did not present antiplasmodial activity.

Marine sponges of the genus *Theonella* have been shown to be a rich source of unique bioactive secondary metabolites with diverse structures derived from different biosynthetic pathways such as polyketide macrolides, alkaloids, steroids, and peptides. Among these metabolites are the cytotoxic macrolides swinholides,¹ which were isolated also from a marine cyanobacterium,² the cyclic peptides cyclotheonamides,³ oriamide,⁴ keramamides,⁵ and perthamides,⁶ the linear peptides polytheonamides,⁷ koshikamides,⁸ and yaku'amides,⁹ and the cyclic peptolides theopapuamide,¹⁰ papuamides,¹¹ and callipeltin A.¹² Most of these metabolites are composed of both proteinogenic and nonproteinogenic amino acids. The latter nonproteinogenic amino acids are primarily derived from amino-acid precursors incorporating an acetate or propionate extender unit. The cyclic peptides cyclotheonamides,³ oriamide,⁴ keramamides,⁵ discobahamins,¹³ and calyamides¹⁴ contain a high proportion of nonproteinogenic amino acids such as vinylogous amino acids, vinylogous thiazole or oxazole amino acids, α -keto- β -amino acids, and oxidized

amino acids and are cyclized through diamino acids such as lysine, ornithine, or 2,3-diaminopropionic acid. These metabolites are biosynthesized by hybrid PKS-NRPS enzymes characteristic of bacteria, thus suggesting that symbiotic bacteria, in the sponges, synthesize these metabolites.¹⁵ In the course of our ongoing research aimed at the isolation of potential biomedicines from marine invertebrates, we examined a sample of the sponge *Theonella* aff. *swinhoei* collected in Dos de la Baleine, Madagascar. The extract of the sponge material that exhibited antiplasmodial activity ($IC_{50} = 0.30 \mu\text{g/mL}$) was separated on a Sephadex LH-20 column, and the semipure compounds were separated by reversed-phase HPLC on a C_{18} preparative column to afford swinholide A, which turned out to be one of the antimalarial constituents ($IC_{50} = 4.75 \mu\text{g/mL}$), and three new cyclic peptides, cyclotheonellazoles A–C (1–

Table 1. NMR Data (DMSO-*d*₆) of Cyclotheonaeallazole A (1)^a

position	δ_C , type ^b	δ_H (J in Hz)	HMBC correlations ^c	NOE correlations ^d
Hbza 1	166.3, C		Hbza-3, Gly-2a,2b,NH	
2	124.9, C		Hbza-4,4'	
3, 3'	129.4, CH	7.73, d (9.0)	Hbza-4,4', Gly-NH	Hbza-4,4', Gly-2a,2b,NH,
4, 4'	115.0, CH	6.78, d (9.0)	Hbza-3,3'	Hbza-3,3'
5	160.4, C		Hbza-3,3',4,4'	
5-OH		9.96 brs		
Gly 1	168.9, C		Gly-2a,2b, Ala-2,NH	
2	42.7, CH ₂	3.79, dd (16.5, 5.5) 3.89, dd (16.5, 5.5) 8.46, t (5.5)		Hbza-3,3', Gly-NH, Ala-2,NH Hbza-3,3', Gly-NH, Ala-2,NH Hbza-3,3', Gly-2a,2b, Ala-NH
NH				
Ala 1	171.5, C		Ala-2,3, Dpr- α -NH	
2	47.9, CH	4.33, m	Ala-3,NH	Ala-3,NH, Gly-2a,2b, Dpr- α -NH
3	18.6, CH ₃	1.16, d (7.0)	Ala-2,NH	Ala-2,NH, Dpr- α -NH
NH		8.00, d (7.5)		Ala-2,3, Gly-2a,2b,NH
Dpr 1	171.3, C		Dpr-2,3b, Apa-NH	
2	51.1, CH	4.03, m	Dpr- α -NH	Dpr-3a,3b, α -NH, Cya-2, Apa-NH
3	40.9, CH ₂	2.49, m 3.75, m 7.93, d (7.5) 7.85, brs	Dpr- α -NH	Dpr-2,3b, α -NH, β -NH Dpr-2,3a, β -NH Dpr-2,3a,3b, Ala-2,3 Dpr-3a, Cya-NH, Apa-NH
α -NH				
β -NH				
Apa 1	174.9, C		Amoha-3,NH	
2	54.5, CH	4.32, m		Apa-3a,3b,4a,4b,NH, Amoha-NH
3	32.3, CH ₂	1.63, m 2.29, m 1.31, m 1.53, m	Apa-4b,5,NH	Apa-2,3b,4a,5,NH Apa-2,3a,4a,4b,5,NH Apa-2,3a,3b,5 Apa-2,3b,5,NH
4	19.8, CH ₂	0.92, t (7.0) 8.61, d (7.0)	Apa-5 Apa-4a,4b	Apa-3b,4a,4b,NH, Amoha-4 Apa-2,3b,4b,5, Dpr-2, β -NH
5	13.9, CH ₃			
NH				
Amoha 1	163.9, C		Ptt-NH	
2	198.1, C		Amoha-3	
3	60.2, CH	5.04, dd (9.5, 3.5)	Amoha-5,NH	Amoha-4,5,NH, Ptt-2,NH
4	37.1, CH	2.39, m	Amoha-3,5,6b,7	Amoha-2,3,5,NH, Apa-5
5	16.3, CH ₃	0.77, d (7.0)	Amoha-3,6a,6b	Amoha-3,4,6a,6b
6	23.4, CH ₂	1.08, m 1.14, m 0.72, t (7.5) 8.31, d (9.5)	Amoha-5,7 Amoha-6a,6b	Amoha-5,7,NH Amoha-5,7 Amoha-6a,6b Amoha-3,4, Apa-2
7	11.9, CH ₃			
NH				
Ptt 1	164.9, C		Ptt-2,3, Cya-NH	
2	123.6, CH	6.76, d (15.0)	Ptt-3	Ptt-3, Amoha-3, Cya-NH
3	132.6, CH	7.39, d (15.0)	Ptt-2,5	Ptt-2,5, Cya-NH
4	149.7, C		Ptt-2,3,5	
5	123.3, CH	7.85, s		Ptt-3
6	170.7, C		Ptt-5,7,8a,8b	
7	54.6, CH	5.21, m	Ptt-8a,8b	Ptt-8a,8b,10,10',NH
8	39.2, CH ₂	3.02, dd (14.0, 5.5) 3.10, dd (14.0, 4.0)	Ptt-7,10,10'	Ptt-7,10,10',NH Ptt-7,10,10',NH
9	127.6, C		Ptt-7,8a,8b,11,11'	
10, 10'	130.6, CH	7.17, d (8.5)	Ptt-8a,8b	Ptt-7,8a,8b,11,11',NH
11, 11'	115.3, CH	6.68, d (8.5)	Ptt-10,10',12-OH	Ptt-10,10',NH,12-OH
12	156.3, C		Ptt-10,10',11,11',12-OH	
12-OH		9.27, s		Ptt-11,11'
NH		9.40, d (8.0)		Ptt-7,8a,8b,10,10', 11,11', Amoha-3
Cya 1	170.7, C		Cya-2,3a,3b	
2	49.5, CH	4.74, m	Cya-3a	Dpr-2, Cya-3a,3b,NH
3	50.6, CH ₂	2.70, dd (14.0, 6.0) 3.25, m 8.16, d (9.0)	Cya-2	Cya-2,3b Cya-2,3a Dpr- β -NH, Ptt-2,3
NH				

^a500 MHz for ¹H, 100 MHz for ¹³C. ^bMultiplicity and assignment from HSQC experiment. ^cDetermined from HMBC experiment, ¹J_{CH} = 8 Hz, recycle time 1 s, from carbon(s) stated to the indicated proton(s). ^dSelected NOEs from ROESY experiment.

Table 2. NMR Data (DMSO- d_6) of Cyclotheonaellazoles B (2) and C (3)^a

position	cyclotheonaellazole B (2)		cyclotheonaellazole C (3)	
	δ_C , type ^b	δ_H (J in Hz)	δ_C , type ^b	δ_H (J in Hz)
Hbza 1	166.3, C		166.4, C	
2	124.9, C		124.9, C	
3,3'	129.4, CH	7.72, d (8.5)	129.4, CH	7.73, d (8.5)
4,4'	115.0, CH	6.78, d (8.5)	114.9, CH	6.78, d (8.5)
5	160.4, C		160.4, C	
5-OH		9.97 brs		9.95 brs
Gly 1	168.9, C		168.9, C	
2	42.7, CH ₂	3.78, dd (16.0, 6.0)	42.7, CH ₂	3.78, m
		3.88, dd (16.0, 6.0)		3.89, m
NH		8.45, t (6.0)		8.46, t (5.5)
Ala 1	172.1, C		171.5, C	
2	48.5, CH	4.33, dq (7.5, 7.0)	47.7, CH	4.33, dq (7.5, 7.0)
3	19.2, CH ₃	1.15, d (7.0)	18.5, CH ₃	1.16, d (7.0)
NH		8.01, d (7.5)		8.00, d (7.5)
Dpr 1	171.2, C		171.4, C	
2	51.2, CH	4.01, m	51.1, CH	4.03, m
3	41.0, CH ₂	2.45, m	40.6, CH ₂	2.46, m
		3.76, m		3.77, m
α -NH		7.90, d (7.5)		7.94, d (7.5)
β -NH		7.84, brs		7.83, brs
Leu/hAla 1	175.2, C		174.8, C	
2	52.7, CH	4.40, m	55.9, CH	4.27, m
3	38.2, CH ₂	1.26, m	23.3, CH ₂	1.78, m
		2.38, m		2.19, m
4	24.4, CH	1.79, m	11.7, CH ₃	0.99, t (7.0)
5	11.7, CH ₃	0.92, d (6.5)		
6	11.7, CH ₃	0.88, d (6.5)		
NH		8.58, d (7.0)		8.61, d (7.5)
Amoha 1	164.1, C		163.9, C	
2	198.9, C		198.1, C	
3	60.4, CH	5.05, dd (9.5, 3.5)	60.2, CH	5.04, m
4	38.1, CH	2.39, m	37.1, CH	2.39, m
5	16.2, CH ₃	0.76, d (6.5)	16.3, CH ₃	0.77, d (6.5)
6	23.5, CH ₂	1.07, m	23.4, CH ₂	1.08, m
		1.15, m		1.14, m
7	11.9, CH ₃	0.71, t (7.5)	11.9, CH ₃	0.72, t (7.5)
NH		8.36, d (9.5)		8.32, d (9.5)
Ptt 1	165.0, C		165.0, C	
2	123.6, CH	6.76, d (15.0)	123.5, CH	6.76, m
3	132.6, CH	7.38, d (15.0)	132.7, CH	7.39, d (15.0)
4	149.7, C		149.7, C	
5	123.2, CH	7.84, brs	123.3, CH	7.85, brs
6	170.8, C		170.7, C	
7	54.6, CH	5.20, q (7.5)	54.5, CH	5.21, m
8	39.1, CH ₂	3.01, m	39.2, CH ₂	3.02, dd (14.0, 6.0)
		3.08, m		3.09, m
9	127.6, C		127.6, C	
10,10'	130.6, CH	7.16, d (8.0)	130.6, CH	7.16, d (8.5)
11,11'	115.3, CH	6.67, d (8.0)	115.3, CH	6.68, d (8.5)
12	156.3, C		156.3, C	
12-OH		9.27, s		9.26, s
NH		9.39, d (8.0)		9.40, d (8.0)
Cya 1	170.9, C		170.7, C	
2	49.5, CH	4.73, m	49.5, CH	4.74, m
3	50.7, CH ₂	2.68, dd (13.5, 5.5)	50.7, CH ₂	2.70, dd (14.0, 6.0)
		3.25, m		3.25, m
NH				8.15, d (9.5)

^a500 MHz for ¹H, 100 MHz for ¹³C. ^bMultiplicity and assignment from HSQC experiment.

carbon (δ_C 156.3). These eight subunits were assembled to the full planar structure of **1** based on the HMBC correlations of the *p*-hydroxybenzyl amide carbonyl with the NH of Gly, the amide carbonyl of Gly with the NH of Ala, the amide carbonyl of Ala with the α -NH of Dpr, the amide carbonyl of Dpr with the NH of Apa, the amide carbonyl of Apa with the NH of Amoha, the amide carbonyl of Amoha with the NH of Ptt, the amide carbonyl of Ptt with the NH of Cya, and the amide carbonyl of Cya with the β -NH of Dpr and the NOEs of Apa-H-2 with Amoha-NH and Amoha-H-3 with Ptt-NH (Figure 1). These correlations were further supported by additional NOE correlations (Table 1).

The absolute configurations of the stereogenic centers of the amino acids in **1** were determined by a variant of the advanced Marfey's method.¹⁶ Treatment of **1** with $H_2O_2/NaOH$ ¹⁷ followed by acid hydrolysis afforded a mixture of the amino acids derived from **1** where the Amoha was converted to Ile. The sample was split into two portions; one reacted with L-FDAA and the other with D-FDAA. Analysis of the derivatized mixture of amino acids by LC-MS revealed that the Ala, Dpr, Apa, Amoha, Cya, and Ptt are of the L-form. An attempt to treat the cyclic peptide with ozone prior to the hydrolysis failed and did not produce any recognized amino acid. The absolute S-configuration of C-4 of Amoha was determined by comparison of the ^{13}C chemical shifts of the methyl signals in Amoha (C-5, 16.3 ppm, and C-7, 11.9 ppm) with those of L-Ile (C-5, 16.2 ppm, and C-6, 11.6 ppm) in micropeptin DR1056,¹⁸ L-allo-Ile (C-5, 14.1 ppm, and C-7, 12.2 ppm) in micropeptin KT1042,¹⁹ and D-allo-Ile (C-5, 13.8 ppm, and C-6, 12.0 ppm) in aeruginosin GE686.²⁰ On the basis of these arguments structure **1** is proposed for cyclotheonellazole A.

The structure elucidation of cyclotheonellazoles B (**2**) and C (**3**) was accomplished in a similar manner. Both shared the same basic structure with **1**, in which leucine (in **2**) and homoalanine (in **3**) replaced the 2-aminopentanoic acid of cyclotheonellazole A (**1**). Cyclotheonellazole B (**2**) presented an HRESIMS protonated molecule at m/z 1034.3363 corresponding to the molecular formula $C_{45}H_{57}N_9NaO_{14}S_2$ and 22 degrees of unsaturation. Its NMR data (DMSO- d_6 , Table 2) were similar to those of **1**, presenting, in the 1H NMR spectrum, two doublet methyl signals (δ_H 0.88 and 0.92) and an isopropyl-methine proton (δ_H 1.79) instead of the triplet methyl signal and the diastereotopic methylene signals (δ_H 1.53, 1.31) of Apa in **1**. In the ^{13}C NMR spectrum of **2** (Table 2), two new methyl carbons (δ_C 23.6 and 21.0) and a methine carbon (δ_C 24.4) appear instead of the methyl and methylene signals (δ_C 13.9 and 19.8, respectively) of Apa in **1**. Interpretation of the 2D NMR data collected for **2** (Table 2) revealed that the two doublet methyl groups (δ_H 0.88 and 0.92, δ_C 23.6 and 21.0, respectively) were coupled to a methine (δ_H 1.79, δ_C 24.4), which in turn was coupled to a methylene (δ_H 2.38, 1.26, δ_C 38.2). The latter methylene was coupled to an α -methine of an amino acid (δ_H 4.40, δ_C 52.7), which was coupled through a COSY correlation to an amide proton (δ_H 8.58). HMBC correlation of the α -methine (δ_H 4.40) with an amide carbonyl carbon (δ_C 175.2) established this amino acid as Leu. This assignment revealed that the Apa, in **1**, was substituted by a Leu, in **2**, while the rest of the molecule remained identical. The configurations of the stereogenic centers of the amino acids of **2** were established by a modified Marfey's method,^{16,17,21} in which the retention times of the L-FDAA-derivatized mixture of amino acids from **2** were compared with those from **1** (correlated on the basis of their

retention times and molecular MS ions) and by comparison with the retention times of L-FDAA-derivatized D,L-leucine. This procedure established all amino acids as of the L-form. On the basis of these arguments the structure of cyclotheonellazole B was established as **2**.

Figure 2. Schematic illustration of elastase inhibition mechanism.

Cyclotheonellazole C (**3**) presented a positive HRESIMS sodium adduct ion at m/z 1028.2869 corresponding to the molecular formula $C_{43}H_{52}N_9Na_2O_{14}S_2$ and 22 degrees of unsaturation. These findings suggested that **3** contains one methylene less than **1**. The NMR data of **3** (DMSO- d_6 , Table 2) were almost identical with those of **1**. Small differences in the chemical shifts of the proton and carbon signals of the straight-chain nonproteogenic amino acid (Apa in **1**) and the absence of one methylene (in **3** relative to **1**) were the only differences observed, when the NMR spectra of **1** and **3** were compared, identifying the amino acid as homoalanine. The structure of the homoalanine and the full structure of **3** were established unambiguously by the 2D NMR experiments summarized in Table 2. The configurations of the amino acids of **3** were established by a similar procedure to the one used for **2** and by comparison with L-FDAA-derivatized D,L-homoalanine.^{16,17,21} This analysis established that all of the amino acids of cyclotheonellazole C are of the L-form, thus assigning its structure as **3**.

The biological activities of these compounds were tested against the serine protease enzymes chymotrypsin and elastase and the malaria parasite *Plasmodium falciparum*. Cyclotheonellazoles A (**1**), B (**2**), and C (**3**) were inactive against *P. falciparum* (IC_{50} 's $> 20 \mu g/mL$). Cyclotheonellazoles A (**1**), B (**2**), and C (**3**) inhibited chymotrypsin with IC_{50} values of 0.62, 2.8, and 2.3 nM, respectively, and elastase with IC_{50} values of 0.034, 0.10, and 0.099 nM, respectively. On the basis of the X-ray structure of the trypsin-cyclotheonamide A complex that supports the formation of a covalent tetrahedral hemiketal between the α -ketoamide of cyclotheonamide A and Ser195 of trypsin,²² one can assume that the cyclotheonellazole complexes with elastase (and similarly with chymotrypsin) exhibit a tetrahedral transition state involving the keto group of Amoha and Ser195 of elastase, while the side chain of Amoha fits in the enzyme S1 pocket.²³ The negatively charged oxygen

is probably stabilized through a hydrogen bond with the His57 residue in the enzyme, and the cleavage cannot occur because carbon is a poor leaving group (Figure 2). The IC₅₀ values obtained for the inhibition of chymotrypsin and elastase by the cyclotheonellazoles illuminated some structure–activity relationships. Cyclotheonellazole A, which contains a 2-amino-pentanoic acid residue, was found to be the most potent inhibitor. This is probably due to a better compatibility with the enzyme S2 subsite. Cyclotheonellazoles B and C contain the amino acids leucine and homoalanine, and it seems that the length and the branching of the aliphatic chain influence the activity.

In summary, we have isolated three new cyclic peptides, along with the known dimeric polyketide swinholid A, from a *T. aff. swinhoei* sponge collected in Madagascar. Cyclotheonellazoles A–C (1–3) are composed of a high proportion of nonproteinogenic amino acids and are related in structure to oriamide (4), which was isolated a decade ago from a sample of the sponge *Theonella* sp. collected in Sodwana Bay, South Africa.⁴ These cyclic peptides are shown here for the first time to be potent elastase and chymotrypsin inhibitors. The newly isolated cyclotheonellazoles A–C further validate Piel's group's findings concerning the huge diversity of hybrid PKS-NRPS enzymes, characteristic of bacteria, found in *T. swinhoei*.¹⁵ These compounds, which are presumably biosynthesized by such hybrid enzymes, append to the constantly growing list of “nonribosomally” biosynthesized cyclic peptides isolated from *T. swinhoei*. The context of the biosynthesis of these highly active protease inhibitors within the sponge is yet unknown, but they provide us with additional scaffolds that selectively inhibit homologous serine proteases of pharmaceutical significance.

EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotation values were obtained on a Jasco P-1010 polarimeter at the sodium D line (589 nm). UV spectra were recorded on an Agilent 8453 spectrophotometer. IR spectra were recorded on a Bruker Tensor 27 FT-IR instrument (Billerica, MA, USA). NMR spectra were recorded on Bruker Avance and Avance III spectrometers at 500.13 MHz for ¹H and 125.76 MHz for ¹³C. DEPT, COSY-45, gTOCSY, gROESY, gHSQC, gHMBC, and gHMBC spectra were recorded using standard Bruker pulse sequences. NMR chemical shifts were referenced to tetramethylsilane, δ_{H} and δ_{C} = 0 ppm. High-resolution mass spectra were recorded on a Waters MaldiSynapt instrument (ESI), and LCMS spectra were recorded on a Waters Xevo TQD instrument (ESI). HPLC separations were performed on a Merck Hitachi HPLC system (L-6200 Intelligent pump and L-4200 UV–vis detector), a JASCO P4-2080 Plus HPLC system with a multiwavelength detector, and an Agilent 1100 Series HPLC system.

Biological Material. The sponge *Theonella* aff. *swinhoei* (BA-019) was collected in Dos de la Baleine (22°14.857 S, 43°10.892 E), Madagascar, at a depth of 28 m on December 2011. A voucher specimen (RMNH POR 7396) was deposited in the Naturalis Biodiversity Center, The Netherlands.

Extraction and Isolation. The sponge material (139 g dry weight after extraction) was chopped into small pieces and extracted by mixture of 1:1 CH₂Cl₂/MeOH (2 × 1.5 L, each 24 h) to afford 1.2 g of extract. The extract was separated by size exclusion chromatography on a Sephadex LH-20 column eluted with a mixture of 1:1 MeOH/CHCl₃ to afford 12 fractions. Fractions 9–12 (142 mg) were combined and separated on a Sephadex LH-20 column with MeOH as the eluent to afford 12 fractions. Fraction 10 (33.0 mg) was separated by HPLC on a preparative RP-8 column (YMC-Pack C-8 250 × 20 mm, 5 μ m, DAD) with a mixture of 45:55 CH₃CN/H₂O to afford the three pure natural products, cyclotheonellazole A (1) (1.6 mg, retention time (*t*_R) 22.3 min, 0.0952% yield), cyclotheonellazole B (2)

(1.4 mg, *t*_R 25.5 min, 0.0833% yield), and cyclotheonellazole C (3) (1.2 mg, *t*_R 19.8 min, 0.0714% yield).

Cyclotheonellazole A (1): amorphous, colorless material; [α]_D²⁴ –20 (c 0.1, MeOH); UV (MeOH) λ_{max} (log ϵ) 206 (3.51) nm; IR (ATR Diamond) ν_{max} 3381, 1691, 1658, 1641, 1631, 1053, 1033, 699 cm^{–1}; NMR data, Table 1; HRESIMS *m/z* 1042.3029 [M + Na]⁺ (calcd for C₄₄H₅₄N₉Na₂O₁₄S₂, 1042.3027); retention times of AA-dinitrophenyl alanine amide (DAA) derivatives: L-Ala-L-DAA, 11.58 min, L-Ala-D-DAA, 11.37 min; L-Dpr-L-DAA, 20.58 min, L-Dpr-D-DAA, 20.20 min; L-Apa-L-DAA, 15.72 min, L-Apa-D-DAA, 18.16 min; L-Ile-L-DAA, 17.93 min, L-Ile-D-DAA, 20.28 min; L-Ptt-L-DAA, 16.29 min, L-Ptt-D-DAA, 16.31 min; L-Cya-L-DAA, 13.37 min, L-Cya-D-DAA, 12.46 min.

Cyclotheonellazole B (2): amorphous, colorless material; [α]_D²⁴ –45 (c 0.05, MeOH); UV (MeOH) λ_{max} (log ϵ) 259 (3.44) nm; IR (ATR Diamond) ν_{max} 3292, 2963, 2931, 1716, 1670, 1576, 1558, 1206, 1139, 1046, 826, 803, 769, 740 cm^{–1}; NMR data, Tables 2 and S1; HRESIMS *m/z* 1034.3363 [M + H]⁺ (calcd for C₄₅H₅₇N₉NaO₁₄S₂, 1034.3364); retention times of DAA derivatives: L-Ala-L-DAA, 11.72 min; L-Dpr-L-DAA, 20.55 min; L-Leu-L-DAA, 17.61 min, D-Leu-L-DAA, 17.74 min; L-Ile-L-DAA, 18.00 min; L-Ptt-L-DAA, 16.26 min; L-Cya-L-DAA, 13.51 min.

Cyclotheonellazole C (3): amorphous, colorless material; [α]_D²³ –11 (c 0.2, MeOH); UV (MeOH) λ_{max} (log ϵ) 207 (4.15) nm; IR (ATR Diamond) ν_{max} 3321, 2917, 2849, 1658, 1546, 1515, 1207, 1044, 699 cm^{–1}; NMR data, Tables 2 and S2; HRESIMS *m/z* 1028.2869 [M + Na]⁺ (calcd for C₄₃H₅₂N₉Na₂O₁₄S₂, 1028.2871); retention times of DAA derivatives: L-Ala-L-DAA, 11.10 min; L-Dpr-L-DAA, 20.59 min; L-homoAla-L-DAA, 12.28 min, D-homoAla-L-DAA, 12.30 min; L-Ile-L-DAA, 17.88 min; L-Ptt-L-DAA, 16.28 min.

Methods for Determination of the Absolute Configurations.

To determine the absolute configuration of the amino acids, advanced Marfey's analysis was performed. A sample of 0.25 mg of compounds 1–3 was treated with H₂O₂/NaOH (2 h) followed by acid hydrolysis, enabling recovery of Ile from the Amoha moiety and the rest of the free amino acids. The hydrolysis of 1–3 was carried out at 104 °C for 60 min with 500 μ L of 6 M HCl. The solution of 1 was divided into two portions, which were dried under vacuum to afford the dry mixture of amino acids, and the residue was dissolved in 100 μ L of H₂O. One portion was derivatized with L-FDAA and the other with D-FDAA. The hydrolysates of 2 and 3 were evaporated to dryness, and the residues were dissolved in 100 μ L of H₂O. Similar solutions were prepared from the reference amino acids D/L-Leu and D/L-homoalanine. To the latter solution were added 20 μ L of 1 M sodium bicarbonate, per each amino acid in the peptide, followed by L- or D-FDAA (30.5 × 10^{–6} mol/L in acetone) at a molar ratio of 1:1.2 for each amino acid. These solutions were stirred at 40 °C for 60 min. The reactions were quenched by the addition of 20 μ L of 2 N HCl for each amino acid. The solutions were evaporated and dissolved in 250 μ L of CH₃CN. The two samples of L- and D-FDAA derivatives were analyzed by ESI LCMS. The analysis was performed on an Acquity-UPLC (Waters Inc., USA) coupled with a UV detector (Acquity-TUV detector, Waters Inc.) and mass spectrometer (Xevo TQD, Waters Inc.) The stationary phase consisted of a C18 (1.7 μ m, 2.1 × 100 mm) column (Waters Inc.), and the mobile phase compositions were A: 95:5 H₂O/CH₃CN + 0.1% formic acid (FA) and B: CH₃CN + 0.1% FA. The elution gradient was as follows: starting conditions 1 min of 100% A, linear gradient to 40% B over 25 min, and hold for 4 min. Samples of 10 μ L were injected, and the flow rate was 0.5 mL/min. The UV detector was set to 340 nm, while the mass spectrometer was operated in both negative and positive ion modes, scanning between 200 and 650 mass units. The interpretation of the data was conducted after the run on both positive and negative ion modes by MassLynx software (v4.1, Waters Laboratory Informatics).

In Vitro Antiplasmodial Assays. The *P. falciparum* strains utilized and details of the assay protocols have been previously reported.²⁴ The selectivity index was determined as the ratio of cytotoxicity over antiplasmodial activity (expressed in IC₅₀ values).

Protease Inhibition Assays. The samples for biological assays were dissolved in DMSO at a concentration of 1 mg/mL, and the IC₅₀

values were determined by series dilutions that produced a sigmoid-shaped response pattern of the enzyme inhibition versus the concentration of the inhibitor, according to the four-parameter logistic model.²⁵ The assays were made in 96-well plates for the following enzymes.

Chymotrypsin. The assay was performed in a Tris buffer (0.6 g TRIS HCl/100 mL H₂O, pH 7.5). The enzyme and the substrate Suc-Gly-Gly-phenylalanine-*p*-nitroanilide were dissolved in the buffer at a concentration of 1 mg/mL. To each well were added 100 μ L of buffer, 10 μ L of enzyme, and 10 μ L of sample. Then, the plate was placed in the spectrophotometer for 5 min of incubation at 37 °C. Thereafter, to each well was added 100 μ L of substrate solution, and the plate was replaced in the spectrophotometer for the kinetic measurement of the absorbance intensity over 30 min at a wavelength of 405 nm.

Elastase. The assay was performed in a Tris buffer (2.422 g TRIS HCl/100 mL H₂O, pH 8.0). The enzyme and the substrate, *N*-Suc-Ala-Ala-Ala-*p*-nitroanilide, were dissolved in the buffer at a concentration of 75 and 0.9 mg/mL, respectively. A 150 μ L amount of buffer solution, 10 μ L of enzyme, and 10 μ L of sample were added to each well. Then, the plate was placed in the spectrophotometer for 20 min of incubation at 30 °C. Thereafter, 30 μ L of substrate solution was added to each well, and the plate was replaced in the spectrophotometer for the kinetic measurement of the absorbance intensity over 20 min at a wavelength of 405 nm.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnatprod.7b00028.

Spectroscopic data including 1D and 2D NMR spectra and HRMS data of compounds 1–3 and complete 2D NMR data of compounds 2 and 3 (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Tel (S. Carmeli): +972-3-6408550. Fax: +972-3-6409293. E-mail: carmeli@pot.tau.ac.il.

ORCID

Alisson Ledoux: 0000-0002-4052-6336

Shmuel Carmeli: 0000-0002-9641-9943

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors express their gratitude to M. E. Remanev for assistance in sponge collection; Y. Abudi for technical assistance; and N. Tal, the Mass Spectrometry Facility of the School of Chemistry, Tel Aviv University, for the measurements of the mass spectra. The present research was supported in part by a Tel Aviv University internal grant (S.C. and Y.K.). M.I. acknowledges the Ph.D. Fellowship from the School of Chemistry of Tel Aviv University. M.A., A.G.-B., and M.F. gratefully acknowledge financial support from the European Commission and the Regional Council of Reunion Island: BIOMOL-TCN program (Activités Thérapeutiques, Cosmétologiques et Nutraceutiques de Molécules Issues de la Biodiversité Terrestre, Marine et Microbienne de la Zone Sud-Ouest de l'Océan Indien), ERDF (European Regional Development Fund).

■ REFERENCES

(1) Carmeli, S.; Kashman, Y. *Tetrahedron Lett.* **1985**, *26*, 511–514.

(2) Andrianasolo, E. H.; Gross, H.; Goeger, D.; Musafija-Girt, M.; McPhail, K.; Leal, R. M.; Mooberry, S. L.; Gerwick, W. H. *Org. Lett.* **2005**, *7*, 1375–1378.

(3) Nakao, Y.; Oku, N.; Matsunaga, S.; Fusetani, N. *J. Nat. Prod.* **1998**, *61*, 667–670.

(4) Chill, L.; Kashman, Y.; Schleyer, M. *Tetrahedron* **1997**, *53*, 16147–16152.

(5) Tsuda, M.; Ishiyama, H.; Masuko, K.; Takao, T.; Shimonishi, Y.; Kobayashi, J. *Tetrahedron* **1999**, *55*, 12543–12548.

(6) Festa, C.; De Marino, S.; Sepe, V.; Monti, M. C.; Luciano, P.; D'Auria, M. V.; Debitus, C.; Bucci, M.; Vellecco, V.; Zampella, A. *Tetrahedron* **2009**, *65*, 10424–10429.

(7) Hamada, T.; Matsunaga, S.; Fujiwara, M.; Fujita, K.; Hirota, H.; Schmicki, R.; Guntert, P.; Fusetani, N. *J. Am. Chem. Soc.* **2010**, *132*, 12941–12945.

(8) Fusetani, N.; Warabi, K.; Nogata, Y.; Nakao, Y.; Matsunaga, S. *Tetrahedron Lett.* **1999**, *40*, 4687–4690.

(9) Ueoka, R.; Ise, Y.; Ohtsuka, S.; Okada, S.; Yamori, T.; Matsunaga, S. *J. Am. Chem. Soc.* **2010**, *132*, 17692–17694.

(10) Ratnayake, A. S.; Bugni, T. S.; Feng, X.; Harper, M. K.; Skaliky, J. J.; Mohammed, K. A.; Andjelic, C. D.; Barrows, L. R.; Ireland, C. M. *J. Nat. Prod.* **2006**, *69*, 1582–1586.

(11) Ford, P. W.; Gustafson, K. R.; McKee, T. C.; Shigematsu, N.; Maurizi, L. K.; Pannell, L. K.; Williams, de Silva, E. D.; Lassota, P.; Allen, T. M.; Soest, R. V.; Andersen, R. J.; Boyd, M. R. *J. Am. Chem. Soc.* **1999**, *121*, 5899–5909.

(12) Zampella, A.; D'Auria, M. V.; Paloma, L. G.; Casapullo, A.; Minale, L.; Debitus, C.; Henin, Y. *J. Am. Chem. Soc.* **1996**, *118*, 6202–6209.

(13) Gunasekera, S. P.; Pomponi, S. A.; McCarthy, P. J. *J. Nat. Prod.* **1994**, *57*, 79–83.

(14) Kimura, M.; Wakimoto, T.; Egami, Y.; Tan, K. C.; Ise, Y.; Abe, I. *J. Nat. Prod.* **2012**, *75*, 290–294.

(15) Wilson, M. C.; Mori, T.; Ruckert, C.; Uria, A. R.; Helf, M. J.; Takada, K.; Gernert, C.; Steffens, U. A. E.; Heycke, N.; Schmitt, S.; Rinke, C.; Helfrich, E. J. N.; Brachmann, A. O.; Gurgui, C.; Wakimoto, T.; Kracht, M.; Crusemann, M.; Hentschel, U.; Abe, I.; Matsunaga, S.; Kalinowski, J.; Takeyama, H.; Piel, J. *Nature* **2014**, *506*, 58–62.

(16) Fujii, K.; Ikai, Y.; Mayumi, T.; Oka, H.; Suzuki, M.; Harada, K. *Anal. Chem.* **1997**, *69*, 3346–3352.

(17) Kimura, M.; Wakimoto, T.; Egami, Y.; Tan, K. C.; Ise, Y.; Abe, I. *J. Nat. Prod.* **2012**, *75*, 290–294.

(18) Adiv, S.; Aharonov-Nadborny, R.; Carmeli, S. *Tetrahedron* **2010**, *66*, 7429–7436.

(19) Lifshits, M.; Carmeli, S. *J. Nat. Prod.* **2012**, *75*, 209–219.

(20) Elkobi-Peer, S.; Faigenbaum, R.; Carmeli, S. *J. Nat. Prod.* **2012**, *75*, 2144–2151.

(21) Marfey, P. *Carlsberg Res. Commun.* **1984**, *49*, 591–596.

(22) Lee, A. Y.; Hagihara, M.; Karmacharya, R.; Alberts, M. W.; Schreiber, L. S.; Clardy, J. *J. Am. Chem. Soc.* **1993**, *115*, 12619–12620.

(23) Maryanoff, B. E.; Costanzo, M. J. *Bioorg. Med. Chem.* **2008**, *16*, 1562–1595.

(24) Jansen, O.; Tits, M.; Angenot, L.; Nicolas, J. P.; De Mol, P.; Nikiema, J. B.; Frédérick, M. *Malar. J.* **2012**, *11*, 289.

(25) Sebaugh, J. L. *Pharmaceut. Statist.* **2011**, *10*, 128–134.